Petco Posts 36% Profit Jump in Fiscal Q2

Petco Health and Wellness (NASDAQ:WOOF) reported strong Q2 FY2025 profitability improvements, with diluted EPS swinging to $0.05 from a prior-year loss and Adjusted EBITDA surging 36.4% to $113.9 million. This performance, driven by significant cost discipline and margin expansion, led the company to raise its full-year adjusted EBITDA guidance, despite a 2.3% revenue decline to $1.49 billion, which was in line with expectations. While the quarter marked a clear step forward in execution and profitability, the focus for investors will be on whether these gains can be paired with a return to top-line growth in future periods.

Analysis

Petco's Q2 FY2025 results highlight a successful strategic focus on profitability and operational efficiency, even as top-line growth remains challenged. The company achieved a significant turnaround in profitability, swinging to a GAAP diluted EPS of $0.05 from a prior-year loss of $(0.09), and posted a 36.4% year-over-year increase in adjusted EBITDA to $113.9 million. This bottom-line strength was driven by disciplined cost management, evidenced by a 1.2 percentage point expansion in gross profit margin to 39.3% and improved inventory control. However, this performance contrasts with a 2.3% decline in revenue to $1.49 billion, which was in line with guidance and led by a 3.0% drop in product revenue, while services revenue grew only 0.8%. Management's decision to raise its full-year adjusted EBITDA guidance to a range of $385 million to $395 million signals confidence in sustaining these margin gains. The key investor question remains whether this operational turnaround can eventually be paired with a return to sales growth, especially as the company reaffirms a low single-digit revenue decline for the full year and has delayed its key Vital Care membership program relaunch to 2026.

Key Decisions for Investors

• Investors should assess if the significant improvement in profitability and raised full-year EBITDA guidance adequately compensates for the persistent top-line pressure, presenting a potential value play if the turnaround in margins proves sustainable.
• Caution is warranted due to the reaffirmed forecast for a revenue decline and the delay of the Vital Care program relaunch to 2026, which removes a potential near-term growth catalyst and keeps the stock in 'show-me' territory.
• Key metrics to monitor are comparable sales and services revenue growth in subsequent quarters, as a failure to stabilize the top line could eventually undermine the impressive bottom-line gains achieved through cost-cutting and store closures.